[1. Karadaglić Đ, Pavlović M. Sklerodermija. In: Karadaglć Đ, editor. Dermatologija. Beograd: Vojnoizdavački zavod, Versalpress Beograd; 2000. p. 1721-41.]Search in Google Scholar
[2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50.10.7326/0003-4819-140-1-200401060-00010]Search in Google Scholar
[3. Fabri M, Hunzelmann N. Differential diagnosis of scleroderma and pseudoscleroderma. J Dtsch Dermatol Ges 2007;5(11):977-84.10.1111/j.1610-0387.2007.06311.x]Search in Google Scholar
[4. Mavrogeni S, Bratis C, Manoussakis M. Coronary artery abnormalities in CREST syndrome revealed by cardiovascular magnetic resonance imaging. Can J Cardiol 2011;27:390e5-7.10.1016/j.cjca.2010.12.052]Search in Google Scholar
[5. Tuffanelli DL, Winkelman RK. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962;57:198-203.10.7326/0003-4819-57-2-198]Search in Google Scholar
[6. Barnnett AJ. Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases. Med J Aust 1978;2:129-34.10.5694/j.1326-5377.1978.tb131413.x]Search in Google Scholar
[7. Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis (scleroderma). Clin Rheum Dis 1979;5:5-13.10.1016/S0307-742X(21)00050-3]Search in Google Scholar
[8. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patient with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13:911-6.]Search in Google Scholar
[9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.]Search in Google Scholar
[10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.]Search in Google Scholar
[11. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for scleroderma and sclerodermoid disorders. J Am Acad Dermatol 1996;35:609-14.10.1016/S0190-9622(96)90689-1]Search in Google Scholar
[12. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumtol 2001;28:1573-6.]Search in Google Scholar
[13. Poormoghim H, Lucas M, Fertig N, Medsger TA, Jr. Systemic sclerosis sine scleroderma: demographic, clinical and serologic features and survival in forty-eight patients. Arthritis Rheum 2000;43:444-51.10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G]Search in Google Scholar
[14. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004;22(3 Suppl. 33):S5-13.]Search in Google Scholar
[15. Walker JG, Pope J, Baron M, LeClercq S, Hudson M, Taillefer S, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007;26:1401-9.10.1007/s10067-007-0537-x]Search in Google Scholar
[16. Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Psysican 2008;78(8):961-8.]Search in Google Scholar
[17. Habif TP, Campbell JL, Chapman MS, Dinulos JGH, Zug KA. Skin disease diagnosis and treatment. Philadelphia: Elsevier Mosby; 2005. p. 354-7.]Search in Google Scholar
[18. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008;37:223-35.10.1016/j.semarthrit.2007.05.003]Search in Google Scholar
[19. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laining TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.10.1002/art.11073]Search in Google Scholar
[20. Englert H, Joyner J, Bade R, Thompson M, Morris D, Chambers P, et al. Systemic scleroderma: a spatiotemporal clustering. Int Med J 2005;35:228-33.10.1111/j.1445-5994.2005.00783.x]Search in Google Scholar
[21. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991;283:366-71.10.1007/BF00371817]Search in Google Scholar
[22. Alamanos Y, Tsifetaki N, Voulgari PV. Epidemiology of systemic sclerosis in Northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005;34:714-2010.1016/j.semarthrit.2004.09.001]Search in Google Scholar
[23. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Reumatol 2006;33(5):1004-13.]Search in Google Scholar
[24. Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003;29:211-37.10.1016/S0889-857X(03)00015-2]Search in Google Scholar
[25. Radić M, Martinović Kaliterna D, Fabijanić D, Radić J. Sistemska skleroza-patogeneza, kliničke manifestacije i liječenje. Liječ Vjesn 2010;132:162-8.]Search in Google Scholar
[26. Yoon JC, Elston DM. CREST syndrome treatment and management. Medscape Drug, Disease and Procedures. [updated 2015 Oct 15; cited 2015 Oct 23]. Available from: http://emedicine.medscape.com/article/1064663-treatment]Search in Google Scholar
[27. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology 2005;44:1212-6.10.1093/rheumatology/keh67115870151]Search in Google Scholar
[28. Herrik AL, Worthington A. Genetic epidemiology: systemic sclerosis. Arthritis Res 2002;4:165-8.10.1186/ar40212892712010566]Search in Google Scholar
[29. Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P. HLA markers for susceptibility and expression in scleroderma. J Rheumatol 2005;32(8):1481-7.]Search in Google Scholar
[30. Del Rio APT, Sachetto Z, Sampaio-Barros PD, Marques-Neto JF, Santos Londe AC, Barros Bertolo M. HLA markers for poor prognosis in systemic sclerosis Brazilian patients. Dis Markers 2013;35(2):73-8.10.1155/2013/301415377495624167351]Search in Google Scholar
[31. Hartree N, Harding M, Jackson C. Systemic sclerosis (scleroderma). [cited 2015 Oct 1]. Available from: http://patient.info/doctor/systemic-sclerosis-scleroderma]Search in Google Scholar
[32. Limited scleroderma (CREST syndrome). ). [cited 2015 Oct 1]. Available from: http://www.mayoclinic.org/diseases-conditions/crest-syndrome/basics/definition/con-20031524]Search in Google Scholar
[33. Maitre A, Hours M, Bonneterre V, Arnaud J, Arslan MT, Carpentier P, et al. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 2004;31(12):2395-401.]Search in Google Scholar
[34. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello A, et al. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 2004;77:10-6.10.1007/s00420-003-0462-514530983]Search in Google Scholar
[35. Goodfield MJD, Jones SK, Veale DJ. The connective tissue diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8th ed. London: Wiley-Blackwell; 2010. p. 51.64-51.79.]Search in Google Scholar
[36. Postiglione L, Montagnani S, Riccio A, Montuori N, Sciorio S, Ladogana P, et al. Enhanced expression of the receptor for granulocyte macrophage colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol 2002;29(1):94-101.]Search in Google Scholar
[37. Thibierge G, Weissenbach R. Concretions calcaires souscutanées et sclerodermie. Ann Dermatol Syph 1911;4:129-55.]Search in Google Scholar
[38. Winterbauer RH. Multiple telangiectasia, Raynaud’s phenomenon, sclerodactyly, and subcutanious calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp 1964;114:361-83.]Search in Google Scholar
[39. Frayha RA, Scarola JA, Hulman LE. Calcinosis in scleroderma: a reevaluation of the CREST syndrome (abstract). Arthritis Rheum 1973;16:542.]Search in Google Scholar
[40. Ensz S. Kidney (renal) involvement (main meni). International Scleroderma Network; c1998-2015 [cited 2015 Oct 1]. Available from: http://www.sclero.org/scleroderma/symptoms/renal/a-to-z.html]Search in Google Scholar
[41. Goodfield MJ, Jones SK, Veale DJ. The connective tissue diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s textbook of dermatology. 8th ed. Oxford: Blackwell Publishing; 2010. p. 51.1-51.138.10.1002/9781444317633.ch51]Search in Google Scholar
[42. Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis Mar 2003;62(3):267-9.10.1136/ard.62.3.267175447912594118]Search in Google Scholar
[43. Kawakami T, Soma Y, Mizoguchi M, Saito R. Immunohistochemical analysis of transforming growth factor-beta 3 in calcinosis in a patient with systemic sclerosis and CREST syndrome. Br J Dermatol 2000;143:1097-131.10.1046/j.1365-2133.2000.03860.x11069531]Search in Google Scholar
[44. Merlino G, Germano S, Carlucci S. Surgical management of digital calcinosis in CREST syndrome. Aesthetic Plast Surg 2013;37:1214-9.10.1007/s00266-013-0224-z24142114]Search in Google Scholar
[45. Ngan V. Systemic sclerosis. Derm Net NZ c2003. [updated 2014 Dec 25; cited 2015 Oct 1]. Available from: http://www.dermnetnz.org/immune/systemic-sclerosis.html.]Search in Google Scholar
[46. Limited scleroderma (CREST syndrome). [cited 2015 Oct 1]. Available from: http://www.medicalgeek.com/disease-syndromes-procedures/15910-limited-scleroderma-crest-syndrome.html.]Search in Google Scholar
[47. Raynaud M. De l’asphyxie local de la gangrene symetrique des extremites. Paris: L. Leclerc; 1862.]Search in Google Scholar
[48. Paravina M. Bolesti vezivnog tkiva. In: Paravina M, Spalević Lj, Stanojević M. Tiodorović J, Binić I, Jovanović D. Dermatovenerologija. Niš: Prosveta; 2006. p. 219-28.]Search in Google Scholar
[49. Limited scleroderma (CREST syndrome). [cited 2015 Oct 1]. Available from: www.drugs.com/mcd/limited-scleroderma-crest–syndrome]Search in Google Scholar
[50. CREST Syndrome. [cited 2015 Oct 1]. Available from: http://en.wikipedia.org/wiki/CREST-syndrome]Search in Google Scholar
[51. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004;63:1009-14.10.1136/ard.2003.017673175514515308510]Search in Google Scholar
[52. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007;37:485-94.10.1111/j.1445-5994.2007.01370.x17547726]Search in Google Scholar
[53. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32.10.1002/art.2113115986394]Search in Google Scholar
[54. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33: 269-74.]Search in Google Scholar
[55. Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD, et al. Isolated pulmonary hypertension in scleroderma. Inter Med J 2005;35:28-33.10.1111/j.1445-5994.2004.00646.x15667465]Search in Google Scholar
[56. Batal I, Domsic RT, Medsger TA, Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010;2010:543704.10.1155/2010/543704295849920981312]Search in Google Scholar
[57. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.10.7326/0003-4819-133-8-200010170-0001011033587]Search in Google Scholar
[58. Tarcin O, Tarcin O, Ozcivan M, Aydin H, Tiftikci A. CREST syndrome and Renal involvement. Marmara Med J 2007;20(3):186-9.]Search in Google Scholar
[59. Sugimoto T, Sanada M, Kashiwagi A. Is scleroderma renal crisis with anti-centromere antibody-positive limited cutaneous systemic sclerosis overlooked in patients with hypertension and or renal dysfunction? Nephrology 2008;13(2): 179-80.]Search in Google Scholar
[60. Sugimoto T, Soumura M, Soumura M. Scleroderma renal crisis in a patient with anticentromere antibody-positive limited cutaneous systemic sclerosis. Mod Rheumatol 2006;16(5):309-11.10.3109/s10165-006-0504-4]Search in Google Scholar
[61. Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012;32(3):645-53.10.1007/s00296-010-1697-6]Search in Google Scholar
[62. Tojo J, Ohira H, Suzuki T, Takeda I, Shoji I, Kojima T, et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepathol Res 2002;22:187-95.10.1016/S1386-6346(01)00138-3]Search in Google Scholar
[63. Kouraklis G, Glinavou A, Karatzas G. Primary biliary cirrhosis accompanied by CREST syndrome. South Med J 2002;95(9):1058-9.10.1097/00007611-200295090-00021]Search in Google Scholar
[64. Mavrogeni S, Manoussakis MN, Karagiorga TS, Douskou M, Panagiotakos D, Bournia V, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthitis Rheum 2009;61:1121-9.10.1002/art.2469519644909]Search in Google Scholar
[65. Mavrogeni S, Bratis C, Manoussakis M. Coronary artery abnormalities in crest syndrome revealed by cardiovascular magnetic resonance imaging. Can J Cardiol 2011; 27:390e5-7.10.1016/j.cjca.2010.12.05221474271]Search in Google Scholar
[66. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Campolis C, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed-enhanced magnetic resonance imaging study. Arthritis Rheum 2007;56:3827-36.10.1002/art.2297117968945]Search in Google Scholar
[67. Lachter J, Suissa A, Schiff E, Rosner I. Anemia in CREST syndrome. Isr Med Assoc J 2003:5:449.]Search in Google Scholar
[68. Lauritano D, Bussolati A, Baldoni M, Leonida A. Scleroderma and CREST syndrome: a case report in dentistry. Minerva Stomatol 2011;60(9):443-65.]Search in Google Scholar
[69. Anastasopoulos G, Marinis A, Konstantinidis C, Theodosopoulos T, Fragulidis G, Vassiliou I. Adenocarcinoma of the third portion of the duodenum in a man with CREST syndrome. World J Surg Oncol 2008;6:106.10.1186/1477-7819-6-106256657318828905]Search in Google Scholar
[70. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011;40:78-83.10.1007/s12016-010-8198-y20143182]Search in Google Scholar
[71. Haustein UF. Scleroderma and pseudoscleroderma: uncommon presentations. Clin Dermatol 2005;23:480-90.10.1016/j.clindermatol.2005.01.01916179182]Search in Google Scholar
[72. Mayes MD, Ho KT. Understanding and managing scleroderma. Scleroderma foundation. [cited 2015 Oct 1]. Available from: http://www.scleroderma.org/site/DocServer/UandM.pdf?docID=326]Search in Google Scholar
[73. Marangoni RG, Rocha LF, Del Rio AP, Yoshinari NH, Marquez-Neto JF, Sampaio-Barros PD. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology 2013;52:1520-4.10.1093/rheumatology/ket16323661427]Search in Google Scholar
[74. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009:68:1878-84.10.1136/ard.2008.095836]Search in Google Scholar
[75. Lyons R, Narain S, Nichols C, Satoh M, Reeves WH. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci 2005;1050:217-28.10.1196/annals.1313.023]Search in Google Scholar
[76. Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 2004;10(11):CR615-21.]Search in Google Scholar
[77. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American college of rheumatology / European league against rheumatism collaborative initiative. Artritis Rheumat 2013;65(11):2737-47.10.1002/art.38098]Search in Google Scholar
[78. Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, et al. Items for developing Revised Classification Criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 2012;64(3):351-7.10.1002/acr.20679]Search in Google Scholar
[79. Johnson SR, Fransen J, Khanna D, Baron M, van den Hogen F, Medsger TA Jr, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64(3):358-67.10.1002/acr.20684]Search in Google Scholar
[80. Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign suspicion of systemic sclerosis Ann Rheum Dis 2014;73(12):2087-93.]Search in Google Scholar
[81. Muller-Ladner U, Tyndall A, Czirjak L, Denton C, Matucci-Cerinic M, EUSTAR centres. Ten years EULAR Scleroderma Research and Trial (EUSTAR): what has been achieved? Ann Rheum Dis 2014;73(2):324-7.]Search in Google Scholar
[82. Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology 2015;54:144-51.10.1093/rheumatology/keu288]Search in Google Scholar
[83. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating The American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001;44(3):735-8.10.1002/1529-0131(200103)44:3<735::AID-ANR125>3.0.CO;2-F]Search in Google Scholar
[84. Cutolo M, Matucci Cerinic M. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007;25:663-5.]Search in Google Scholar
[85. Jung P, Trautinger F. Capillaroscopy. J Dtsch Dermatol Ges 2013;11:731-6.10.1111/ddg.12137]Search in Google Scholar
[86. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford) 2006;45(Suppl 4):iv43-6.10.1093/rheumatology/kel310]Search in Google Scholar
[87. Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson M, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol 2007;26:1268-74.10.1007/s10067-006-0489-6]Search in Google Scholar
[88. Hughes M, Moore T, O’Leary N, Tracey A, Ennis H, Dinsdale G, et al. A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis – spectrum disorders. Rheumatology 2015;54(8):1435-42.10.1093/rheumatology/keu53325749623]Search in Google Scholar
[89. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s ph enomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58(12):3902-12.10.1002/art.2403819035499]Search in Google Scholar
[90. Larche M. What’s new in Scleroderma. [cited 2015 Oct 1]. Available from: http://static1.squarespace.com/static/5280f5e9e4b0c046bfaad504/t/52decb0ee4b0fb2ead9eb0ba/1390332686069/Whats+new+in+Scleroderma+8th+Jan+2014.pdf.]Search in Google Scholar
[91. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.10.1016/j.semarthrit.2005.03.00516084222]Search in Google Scholar
[92. Karp DR, Marthandan N, Marsh SG, Ahn C, Arnett FC, Deluca DS, et al. Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis. Hum Mol Genet 2009;19(4):707-19.10.1093/hmg/ddp521280736519933168]Search in Google Scholar
[93. Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK, et al. Major histocompability complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010;69(5):822-7.10.1136/ard.2009.111906291670219596691]Search in Google Scholar
[94. Loubiere LS, Lambert NC, Madeleine MM, Porter AJ, Mullarkey ME, Pang JM, et al. HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women. Rheumatology 2005;44(3):318-22.10.1093/rheumatology/keh48915572392]Search in Google Scholar
[95. Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007;357:1210-20.10.1056/NEJMoa06765517881752]Search in Google Scholar
[96. Beretta L, Rueda B, Marchini M, Santaniello A, Simeon CP, Fonollosa V, et al. Analysis of class II human leucocyte antigens in Italian and Spanish systemic sclerosis. Rheumatology 2012;51(1):52-9.10.1093/rheumatology/ker335327629322087014]Search in Google Scholar
[97. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010;2(6):863-78.10.2217/imt.10.69305951121091117]Search in Google Scholar
[98. Morita A, Kobayashi K, Isomura I, Tsuji T, Krutman J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43:670-4.10.1067/mjd.2000.10516511004624]Search in Google Scholar
[99. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumathology 2005;44:145-50.10.1093/rheumatology/keh39015546967]Search in Google Scholar
[100. Goundry B, Bell L, Langtree M, Moorthy A, BMJ. Diagnosis and management of Raynaud’s phenomenon. BMJ 2012;344:e 289.10.1136/bmj.e28922315243]Search in Google Scholar
[101. Rybalkin SD, Yan C, Bornfeldt K, Beavo J. Cyclic phosphodiesterases and regulation of smooth muscle function. Circ Res 2003;93:280-91.10.1161/01.RES.0000087541.15600.2B12933699]Search in Google Scholar
[102. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005;64:1387.10.1136/ard.2004.034488175563316100356]Search in Google Scholar
[103. Rajagopalan S, Pfenninger D, Somers E, Kehrer C, Chakrabarti A, Mukherjee D, et al. Effects of Cilostazol in patients with Raynaud’s syndrome. Am J Cardiol 2003;92:1310-5.10.1016/j.amjcard.2003.08.01314636909]Search in Google Scholar
[104. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, et al. Efficacy and tolerability of a selective alpha(2c)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004;50(12):3994-4001.10.1002/art.2066515593189]Search in Google Scholar
[105. Anderson ME, Moore TL, Hollis S, Jayson MIV, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford) 2002;41:324-8.10.1093/rheumatology/41.3.32411934971]Search in Google Scholar
[106. Cukierman T, Elinav E, Korem M, Chajek-Shaul T. Low dose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 2004;63:1341-3.10.1136/ard.2003.014431175476915361398]Search in Google Scholar
[107. Sparsa A, Lesaux N, Kessler E, Bonnetblanc JM, Blaise S, Lebrun-Ly V, et al. Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol 2005;53:S263-5.10.1016/j.jaad.2005.04.01016227105]Search in Google Scholar
[108. Chamberlain AJ, Walker NP. Successful palliation and significant remission of cutanous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg 2003;29:968-70.]Search in Google Scholar
[109. Saddic N, Miller JJ, Miller OF 3rd, Clarke JT. Surgical debridement painful fingertip calcinosis cutis in CREST syndrome. Arch Dermatol 2009;145:212-3.10.1001/archderm.145.2.212-b19221282]Search in Google Scholar